Arne Scheu

Company: Valink Therapeutics

Job title: Co-Founder & Chief executive officer

Bio:

Arne is Co-Founder and CEO of Valink Therapeutics. Following his research on protein conjugation technologies at the University of Oxford, he founded Valink Therapeutics as a spin-out of the Department of Biochemistry with the support of the Y Combinator startup accelerator; the company combines his passions for protein engineering and drug discovery. Arne holds a DPhil (PhD) in Biochemistry from the University of Oxford, has been awarded the Rhodes Scholarship for Germany, and has been listed as Forbes 30 Under 30 Europe 2024.

Seminars:

Increasing Tissue Penetration & Limiting Immunogenicity: Differentiating Through Novel Conjugate Design 1:40 pm

Targeting proteins expressed in a larger number of cancers versus receptors predominantly expressed in solid tumor subsets Increasing tissue penetration propensity to achieve more significant internalization and intracellular exposure to the payload with smaller proteins  Leveraging reduced screening cycles required to optimize linker chemistry with smaller proteins, and modulatory to conjugate different payload typesRead more

day: Conference Day Two